Inception 3, Inc.

Necessity mothered the build-to-buy strategy. Some thought good times might kill it. At a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate

SAN FRANCISCO — The “build-to-buy” biotech partnering model is still a viable business strategy, even amid the economic rebound, big pharma and venture capital execs said at the recent CALBIO meeting.

Financings During the second quarter of 2014 start-up companies raised a total of $893.9 million, a 25% drop from the previous quarter’s $1.18 billion, which was the biggest quarter for start-up fundr

As it pivots into a new, smaller fund, life sciences investment firm Versant Ventures is devoting a sizable amount of its biopharma portfolio to deals that in past years VCs have considered anathema,